Pathogenesis of obesity by Vassallo, Josanne
Pathogenesis of obesity
The escalating prevalence of obesity worldwide is an ever 
increasing source of concern to disease surveillance units, health 
monitoring agencies and healthcare providers globally. Resource 
allocation in healthcare has had to be tailored to the management 
of this global epidemic. However the key to success in tackling 
this problem lies in prevention and this in itself mandates a 
thorough understanding of the physiology of weight control 
and the pathogenesis of obesity. The development of obesity is 
undoubtedly multifactorial with the major underlying causes 
being inappropriate diet and lifestyle. Genetic factors have 
been shown to modulate the phenotypic expression of obesity. 
Medications such as steroids and endocrine disorders such as 
hypothyroidism can also lead to disturbances in the normal 
physiology of weight control in a small percentage of instances. 
However in the vast majority of weight problems and obesity, 
the aetiology is a mismatch between food intake and energy 
expenditure. 
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The	physiological	basis	of	obesity
A complex feedback control system 
consisting of a central processing unit 
which receives afferent signals and 
generates appropriate efferent stimuli in 
response controls food intake, satiety and 
subsequently weight.
Age and gender differences in food 
intake have been identified with an 
increase in adolescence, peaking in the 
second decade after which it declines.1 
Men tend to eat more than women in 
keeping with their higher fat free mass.2 
An age-related decrease in food intake is 
associated with a slow decline in energy 
expenditure and in middle age the latter is 
faster than the former. Concomitantly the 
decline in sex steroid levels occurring in 
the perimenopause results in an increase 
in visceral fat and an increased risk of the 
development of the metabolic syndrome 
(Figure 1). The latter is a constellation 
of manifestations originally described 
by Gerald Reaven in 1993 comprising 
obesity, insulin resistance and increased 
atherosclerotic risk with diabetes, 
hypertension and hyperlipidaemia.3 
The	regulatory	control	system
The feedback system regulating body 
weight and appetite is the target of ongoing 
intense research with appreciation of the 
complexity of this system increasing as new 
modulators and players are identified.
Afferent	signals	
Gastric distension via activation of 
vagal afferents is a signal for satiety, with 
gastric contractions signalling for hunger. 
Nutrients, neural impulses and hormones 
themselves act as afferent signals in the 
regulation of energy intake and expenditure 
(Figure 2). Nutrient absorption eg that of 
glucose4 initiates a sensation of satiety 
whereas a fall in glucose promotes hunger. 
This effect is itself mediated by different 
neurotransmitters, hormones and peptides
Leptin5 is a peptide produced by 
adipocytes which has been closely 
correlated with fat mass, with secretion 
increasing as fat deposition increases. It 
acts to reduce food intake  and is believed 
to increase sympathetic nervous system 
activity.6 This peptide has found use in a 
small number of individuals who have been 
shown to be deficient in the leptin gene.
Another important peptide is Growth 
Hormone (GH) relin which is secreted by 
the stomach and duodenum and has been 
shown to stimulate GH secretion. It is an 
endogenous ligand for the GH receptor. 
GH relin increases food intake and its 
secretion is in turn suppressed by food 
intake.7-9 Serum concentrations increase in 
anticipation of a meal. Its secretion has 
been shown to increase after diet- and 
exercise-induced weight loss and is believed 
to be one of the reasons why lifestyle 
modification does not lead to permanent 
weight loss. 
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Stimulatory	 Inhibitory
GH releasing hormone Leptin
Neuropeptide Y Cholecystokinin
Melanin-concentrating hormone Enterostatin
Opioids  Serotonin
Norepinephrine CRH/urocortin
 Alpha melanocyte stimulating hormone
 Glucagon-like peptide 1
Table	1:	Monoamines and peptides that affect feeding
Figure	1: Features of the metabolic syndrome
Figure	2: Overview of the integrated regulatory pathway
Other peptides that have been shown 
to reduce food intake are cholecystokinin 
(CCK), 10 enterostatin11 and polypeptide Y 
3-36.12 The list of peptides is ever on the 
increase but the precise interaction between 
them and their relevance in humans awaits 
the outcome of further research (Table 1).
Central	processing	unit
Afferent impulses proceed centrally 
to the hindbrain and the hypothalamus 
for integration and processing. A number 
of specific anatomical sites have been 
implicated as a result of in vivo studies 
generally involving destruction of the said 
area and observation of outcomes.13 The 
nucleus of the tractus solitarius in the 
hindbrain is the site where vagal and other 
neural input are integrated.
The arcuate nuceus at the base of the 
hypothalamus receives signals from leptin 
and in turn increases both production 
and secretion of neuropeptide Y (NPY) 
and Agouti-related peptide(AgRP) thereby 
increasing food intake. On the other hand, 
cocaine-amphetamine-related transcript 
(CART) and pro-opiomelanocortin (POMC) 
decrease food intake.
The paraventricular nucleus of the 
hypothalamus is itself stimulated by 
peptides from arcuate nucleus and 
relays signals further. Destruction of the 
ventromedial hypothalamus has been 
show to lead to increased food intake and 
subsequently obesity in animals treated 
experimentally. The lateral hypothalamic 
nucleus in turn exerts opposite effects 
such as decreased feeding and lowering 
body weight. Furthermore specific areas of 
the amygdale can affect feeding partially 
through the ventromedial hypothalamus. 
Efferent	mediators
The peripheral nervous system has a 
definite role in stimulating thermogenic 
tissues via activation of beta 3 adrenergic 
receptors resulting in a reduction in food 
intake.14 The sympathetic nervous system 
plays a tonic role in maintaining energy 
expenditure. Amongst the hormones 
that interact at the efferent end of the 
regulatory system, glucocorticoids are 
believed to play an important permissive 
role15 these effects possibly mediated 
via the sympathetic nervous system. For 
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example, it has been noted that leptin 
deficiency does not result in obesity in the 
absence of glucocorticoids. 
Factors	affecting	
energy	expenditure
Seventy percent of daily energy 
expenditure in man is utilised in 
maintaining basal metabolic processes 
whereas ten percent is utilised in the 
thermic response to food. An inter-
individual variation has been noticed 
in humans which is believed to be 
multifactorial:
a) A strong relationship between total daily 
expenditure or resting energy expenditure 
and fat free mass is present. Therefore 
it is believed that differences in fat free 
mass account for approximately 80% of  
variance.16
b) The sedentary lifestyle prevalent in the 
Western world definitely contributes 
significantly to the ever increasing 
prevalence of obesity.17,18
c) Activity and exercise including 
spontaneous physical activity such as 
fidgeting can account for one to eight 
hundred kcal energy expenditure per 
day.16, 19
 
Genetics	of	obesity
Obesity can be either monogeneic or 
polygenic in inheritance. Five single gene 
defects have been identified:
a) Agouti	gene: The protein binds 
to melanocortin-4 receptor in the 
hypothalamus thereby modulating food 
intake. Concentrations have been found 
to be higher in obese than non-obese 
men and correlate well with basal 
metabolic index (BMI).20  A related 
gene which has been identified is the 
mahogany gene.21
b) Leptin	gene: Leptin is produced in fat 
cells, the gut, and the placenta and 
signals the brain about the amount 
of stored fat.22,23  Deficient mice have 
hyperphagia, insulin resistance and 
infertility. In humans leptin may act 
on the arcuate nucleus to decrease NPY 
production (which usually stimulates 
food intake). Obesity due to leptin 
deficiency has been reported in two 
families, affected subjects responding 
well to leptin therapy.24,25 In contrast 
the majority of obese subjects have a 
high level of circulating leptin level 
suggesting a level of leptin resistance.26
c) Leptin	receptor	gene:	Leptin receptor 
deficiency secondary to mutations in the 
leptin receptor gene has been reported in 
humans.27
d) Melanocortin-428	and	melanocortin-3	
receptor	gene	defects29: Transgenic 
mice with mutations in these genes 
exhibit hyperphagia and severe obesity. 
Observations in these mice suggest that 
receptors for MSH normally inhibit food 
intake and fat accumulation.
e) Serotonin subtype receptor elimination 
in transgenic mice results in similar 
manifestations.30 
Genetic	factors
The heritability of weight, metabolic 
rate, thermic responses to food and 
spontaneous physical activity has been 
studied in families which included twins 
or adoptees. Twins separated at birth 
maintained the same characteristics 
regarding weight control despite different 
environmental backgrounds. Similarly 
studies in adopted children showed that 
regulation of weight and body composition 
was similar to that of biological parents 
and differered from that of the adoptive 
parents.31,32 
A number of genetic syndromes 
featuring obesity have also been described 
in the literature and are associated with 
chromosomal aberrations as in the Prader 
Willi Labhart syndrome.33 
Studies to identify genetic abnormalities 
in common obesity have so far proved 
unsuccessful, not an common situtation in 
polygenic disorders.34 A number of candidate 
genes have been analysed such as the beta3 
receptor gene,35 peroxisome proliferators-
activated-receptor (PPAR) gamma36, and 
melanocortin-4 (MCR-4) receptor.37,38
Conclusion
Obesity is a multifactorial and complex 
disorder that has significant implications 
for affected subjects and the healthcare 
services that have to deal with the 
consequences of this disorder. For example, 
a recently identified genetic polymorphism39 
in 10% of  4 study populations in the 
United States (rs7566605 on chromosome 
2q14.1) can be expected to have a 
significant impact on health and healthcare 
despite being associated with only a low 
relative risk. Further research into the 
physiology and pathophysiology of obesity 
should hopefully enable the development 
of preventive and therapeutic strategies to 
curb the obesity epidemic.
1. Obesity has reached epidemic proportions worldwide
2. The pathogenesis of obesity is multifactorial with genetic and environmental/
lifestyle mediators playing a role
3. A complex regulatory system exists comprised of a central processing unit which 
analyses and responds to afferent input and sends out efferent messages
4. A number of genetic mutations presdisposing to obesity have been identified in 
animals and humans
5. The major cause of obesity is energy intake/output mismatch 
Practice	Points
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